Talazoparib
- Generic Name
- Talazoparib
- Brand Names
- Talzenna
- Drug Type
- Small Molecule
- Chemical Formula
- C19H14F2N6O
- CAS Number
- 1207456-01-6
- Unique Ingredient Identifier
- 9QHX048FRV
- Background
Talazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair.
...
- Indication
Talazoparib is indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer. This indication is approved by the FDA, EMA, and Health Canada.
...
- Associated Conditions
- HRR gene-mutated (HRRm) metastatic castration-resistant prostate cancer (mCRPC), Metastatic Breast Cancer, Locally Advanced Breast Cancer (LABC)
- Associated Therapies
- -
Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-12-11
- Last Posted Date
- 2016-07-26
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT02627430
Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
- Conditions
- Head and Neck Squamous Cell CarcinomaStage III MesotheliomaStage IIIC Ovarian CancerStage IV Ovarian CancerMetastatic Pancreatic AdenocarcinomaStage IIIA Non-Small Cell Lung CancerStage IV Non-Small Cell Lung CancerTriple-Negative Breast CarcinomaStage IIIA Ovarian CancerStage IIIA Small Cell Lung Carcinoma
- Interventions
- First Posted Date
- 2015-10-05
- Last Posted Date
- 2017-04-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT02567396
Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors
- First Posted Date
- 2015-09-01
- Last Posted Date
- 2016-02-11
- Lead Sponsor
- Washington University School of Medicine
- Registration Number
- NCT02537561
Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies
- Conditions
- Interventions
- First Posted Date
- 2015-03-19
- Last Posted Date
- 2021-02-09
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 43
- Registration Number
- NCT02392793
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Testing the Addition of the Anti-Cancer Drug Talazoparib to the Combination of Carboplatin and Paclitaxel for the Treatment of Advanced Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-12-17
- Last Posted Date
- 2023-08-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 43
- Registration Number
- NCT02317874
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
Talazoparib in Treating Patients with Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes
- Conditions
- Interventions
- First Posted Date
- 2014-11-10
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 150
- Registration Number
- NCT02286687
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer
- First Posted Date
- 2014-11-04
- Last Posted Date
- 2022-07-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 36
- Registration Number
- NCT02282345
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-06-03
- Last Posted Date
- 2023-06-01
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 1864
- Registration Number
- NCT02154490
- Locations
- 🇺🇸
Riverside Methodist Hospital, Columbus, Ohio, United States
🇺🇸Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
🇺🇸Los Angeles County-USC Medical Center, Los Angeles, California, United States
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
- Conditions
- Interventions
- First Posted Date
- 2014-04-17
- Last Posted Date
- 2021-03-26
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT02116777
- Locations
- 🇺🇸
Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States
🇺🇸UCSF Medical Center-Mission Bay, San Francisco, California, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)
- Conditions
- Interventions
- First Posted Date
- 2014-01-14
- Last Posted Date
- 2019-10-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 84
- Registration Number
- NCT02034916
- Locations
- 🇺🇸
Marin Cancer Care, Inc., Greenbrae, California, United States
🇺🇸UCLA Hematology-Oncology, Santa Monica, California, United States
🇺🇸Stanford Cancer Institute, Stanford, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.